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Similar to solid tumors, acute leukemia growth induces neo-vascularization (angiogenesis) within the bone marrow (BM) microenvironment. Several studies have shown that acute myeloid leukemia (AML) cells release angiogenic growth factors such as vascular endothelial growth factor (VEGF) within the BM. In turn, AML growth and expansion involves the activation of BM vessels, resulting in a paracrine stimulation of leukemia, similar to what is seen in solid neoplasms. In addition, we and others have shown that subsets of acute leukemias also express VEGF receptors; in these cases, autocrine stimulation of leukemia cells by VEGF may result in proliferation, migration and resistance to chemotherapy. [1] [2] [3] Therefore, exposure of the BM microenvironment to increased VEGF levels may in fact contribute toward leukemia expansion via paracrine or autocrine stimulation of subsets of leukemia cells.
More recently, we have shown that acute lymphocytic leukemia expansion and the onset of extramedullary disease involved migration of leukemia cells, within the BM microenvironment and into the peripheral circulation. 4 This migration was induced at least partly due to VEGF/PLGF (placental derived growth factor) stimulation of leukemia cells within the BM. However, the molecular mechanisms involved in this migration were not characterized, and are the subject of the present study.
Although several reports have implicated the cell cytoskeleton, namely actin and tubulin, in the migration of different cell types, few have studied its importance in VEGF-induced leukemia cell migration.
VEGF or PLGF stimulation of AML cell lines resulted in a significant increase in cell migration over control (nonstimulated) cells (Figure 1a ). PLGF (which binds only FLT-1 (fms-related tyrosine kinase 1)) was more potent at inducing AML migration than VEGF itself ( Figure 1a , the difference between PLGF and VEGF stimulation versus control condition, Po0.05); accordingly, the migratory effects of VEGF were blocked by the use of an FLT-1 tyrosine kinase inhibitor (IR1; IC 50 ¼ 2.0 mM) and also by the small interfering RNA designed to block FLT-1 expression (Figure 1a ). In contrast, PLGF/VEGF addition produced a modest effect on AML cell proliferation/ survival (see Supplementary Figure 1A) .
Next, we characterized the mechanisms whereby PLGF induced leukemia migration. PLGF stimulation of HEL and HL60 cell lines in vitro resulted in the formation of FLT-1 membrane protrusions (Figure 1b) . Similar results regarding FLT-1 localization after PLGF stimulation were obtained by studying two BM samples obtained from AML patients (M3 and M4). In addition, we verified whether PLGF stimulation induced FLT-1 tyrosine phosphorylation (Figure 1c) . Importantly, coincubation with the FLT-1 inhibitor (IR1) blocked PLGF-induced protrusion formation (Supplementary Figure 1B) and FLT-1 phosphorylation (Figure 1c ). Phalloidin staining (which identifies polymerized actin) indicated that these PLGF-induced membrane protrusions consisted of polymerized actin bundles which co-stained with FLT-1 (Supplementary Figure 2A) . PLGF treatment clearly resulted in the formation of phalloidin-stained membrane protrusions (Supplementary Figure 2B ; Po0.01 between PLGF and control conditions).
Regarding the activation of downstream signalling pathways, PLGF induced extracellular signal-regulated kinase 1/2 (ERK1/2) and P38 phosphorylation, but did not induce Akt phosphorylation (Figure 2a ). In addition, we also investigated the involvement of Rho-GTPases in modulating the effects of PLGF. As shown in Figure 2b , PLGF stimulation resulted in Rac-1 and RhoA induction, whereas Cdc42 was not affected. Concerning the activation of p21-activated kinase (PAK), an enzyme known to be activated by other receptor tyrosine kinases, there was an increase in PAK-1 phosphorylation following PLGF stimulation (Figure 2c ). We also observed that cofilin, a small actin-binding protein known to promote the regeneration of actin filaments, is activated by PLGF stimulation (Figure 2c ).
As we had previously implicated Hsp90 as being part of protein:protein complexes that modulate some of the intracellular signals following VEGF stimulation of leukemia cells, 5 we investigated whether PLGF signalling also involved Hsp90. As shown in Figure 2d , PLGF promoted the recruitment of Hsp90 and its binding to actin and FLT-1; these interactions were blocked by co-incubation with the FLT-1 inhibitor IR1 (Figure 2d ). In contrast, the microtubular cytoskeleton had a modest interaction with FLT-1 or Hsp90 (Supplementary Figure 3) .
Taken together, the data obtained suggest that PLGF stimulation of AML cells results in ERK1/2 and P38 phosphorylation, Rac1, RhoA, PAK1 and cofilin activation, together with the formation of protein:protein complexes at the cell membrane, which involve actin, FLT-1 and Hsp90. Importantly, these results were obtained in AML cell lines and also in primary leukemia samples (not shown).
Next, we investigated the formation and possible involvement of lipid domains such as caveolae or lipid rafts in modulating the effects of PLGF on AML cells. The caveolin scaffolding domain (amino acids 82-101) of caveolin-1 recognizes characteristic peptide sequences named as caveolin-binding domains within a variety of signalling molecules and several growth factor receptors. 6 We carried out a SWISSPROT database search and found that human FLT-1 sequence has one caveolin-1 scaffolding domain with extracellular localization and three other caveolin-1 scaffolding domains in the cytoplasmic region (Supplementary Figure 4) , suggesting that caveolae might be involved in the activation of signalling pathways leading to cell migration. Thus, we reasoned that PLGF might promote the interaction between FLT-1 and caveolin-1, and might also increase the levels of intracellular caveolin-1. As determined by electron microscopy ( Figure 3a ) and Western blotting (Supplementary Figure 5A) , PLGF stimulation increased the levels of caveolin-1 and the number of caveolae-like structures on AML cells. These results suggested that the formation of caveolae-like structures might be involved in modulating the activation of signalling pathways by PLGF. Accordingly, as determined by immunoprecipitation of AML protein extracts, FLT-1 interacts with actin, Hsp90 and caveolin-1 (Supplementary Figure 5B) .
As PLGF stimulation resulted in the formation of actin protrusions, activation of Rho GTPases and other downstream protein kinases (PAK) and the formation of protein:protein complexes that included actin, we reasoned that an agent that disrupted the actin cytoskeleton might impede PLGF-induced AML migration. We used cytochalasin D, an actin-depolymerizing agent, for this purpose. AML cells treated with cytochalasin D showed a blockage of PLGF-induced leukemia migration Figures 6A and B) . Interestingly, the effects of cytochalasin D (at 30 min) involved blocking of membrane protrusions formation (Supplementary Figure 7A) and blocking of P38 and cofilin activation ( Figure 3b ). As expected, the interaction between FLT-1, Hsp90 and caveolin-1 at the cell membrane was also impeded in cytochalasin D-treated cells (Supplementary Figure 7B) . In contrast, a microtubule-disrupting agent (taxol, used as a control) did not impede PLGF-induced formation of membrane protrusions (Supplementary Figure 8 ) or activation of the downstream signalling pathways mentioned above (data not shown), suggesting that these agents may block cell migration via other mechanisms.
In acute lymphoblastic leukemia patients, the detection of persistent circulating leukemia blasts is a bad prognostic factor 7 and may correlate with resistance to chemotherapy. Recently, we revealed some of the molecular bases for the uncontrolled exit of leukemia blasts from the BM; in subsets of acute leukemia, the expression and activation of VEGFR-1 (FLT-1) leads to differential localization of leukemia cells within the BM, resulting in the early exit of FLT-1-positive leukemia blasts into the peripheral circulation and decreased survival of inoculated recipients. 4 Others have shown that FLT-1 activation results in modulation of cell movement in myelodysplastic syndromes, 3 and other BM diseases such as myeloma and chronic leukemias. Therefore, we sought to define the signalling intermediates/ signalling pathways involved in FLT-1-induced leukemia cell migration, using AML cell lines and primary leukemias as models.
To date, few studies have focused on the characterization of signalling pathways downstream of VEGF receptors in malignant cells. We have previously shown that VEGFR-2 activation on subsets of AML cells results in receptor phosphorylation, MAP/ERK kinase activation, Hsp90 recruitment and binding to APAF-1 and finally Bcl-2 overexpression (and protection from apoptosis). 5 In contrast to the mitogenic effects of kinase insert domain receptor (KDR), FLT-1 stimulation of AML cells largely results in cell migration, whereas proliferation is marginally affected. Leukemia stimulation by VEGF or PLGF resulted in the formation of actin membrane protrusions, where FLT-1 accumulated and was detected in its phosphorylated form. Whereas ERK1/2 and the Pi3 kinase/Akt pathways were only marginally affected, P38 phosphorylation was strongly induced by VEGF/PLGF stimulation. Accordingly, selective pharmacological inhibition of P38 (with SB203580) blocked PLGF-induced AML migration (data not shown).
Concerning the actin cytoskeleton, in line with numerous reports showing that activation of Rho GTPases is essential for cell migration processes, we show that PLGF stimulation leads to Rac-1 and RhoA phosphorylation, accompanied by PAK1/2 and cofilin phosphorylation. In addition, VEGF/PLGF stimulation increases the interaction between FLT-1 and Hsp90, Given that FLT-1 has, in its coding sequence, caveolinbinding domains, we reasoned that the interactions seen might also involve caveolin-1. VEGF/PLGF stimulation of AML cells induced the formation of caveolae-like vesicles. Immunoprecipitation experiments using caveolin-1 antibody suggested that FLT-1 interacts with caveolin-1, and is involved in a protein complex with Hsp90 and actin. Previous studies performed on endothelial cells had shown that similar interactions occur following VEGFR-2 stimulation, and are directly linked to actin and cell migration; one report has specifically suggested that Hsp90 interacts specifically with VEGFR-2 on endothelial cells. 8 As we used PLGF as the main stimulator of AML cell migration, we suggest that the reported effects are exerted mainly via FLT-1. However, we cannot overrule possible crosstalks between other VEGF receptors, namely VEGFR-2, expressed by AML cells.
Interestingly, the use of cytochalasin D to block cell migration (as it impedes actin bundle formation) also blocked PLGFinduced P38 phosphorylation, caveolin-1 induction and Hsp90 recruitment. Notably, these effects are produced after a short exposure of AML cells to the drug (30 min), suggesting that actindisrupting agents affect cell migration by impeding cell cytoskeletal rearrangements but may also block the activation of specific signalling intermediates involved in the overall migration process.
Our proposed model of the molecular changes occurring after VEGF/PLGF activation of AML cells is depicted in Figure 3c . 
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Letters to the Editor
Recently, we reported the first case of donor-derived adult T-cell leukemia (ATL) after allogeneic stem cell transplantation (SCT) from a human T-cell leukemia virus type I (HTLV-I)-seropositive donor.
1 Southern blot analysis showed no significant clonal proliferation of HTLV-I-infected cells in the donor, and it remained unclear whether donor-derived ATL cells originated from T cells that were infected with HTLV-I in the donor. HTLV-I provirus load -the percentage of HTLV-I-infected cells among peripheral blood mononuclear cells (PBMCs) -was 1.3% in the donor, as most lymphocytes in asymptomatic carriers are not infected with HTLV-I. Accordingly, the donor-derived ATL may have developed in T cells that were newly infected with HTLV-I in the recipient after SCT. 2 As a follow-up to our earlier report, we have now demonstrated, using tumor-specific polymerase chain reaction (PCR) methods, that the HTLV-I-infected clone, which is identical to the donor-derived ATL cells, is present among PBMCs of the donor, indicating that the donor-derived ATL cells were infected with HTLV-I in the donor before SCT. The host immune-suppressive conditions involved in the development of donor-derived ATL, based on the expression of tax gene transcripts in the donor-derived ATL cells, are described below.
A 44-year-old Japanese man with refractory lymphoma-type ATL underwent SCT from his human leukocyte antigen (HLA)-identical, 40-year-old brother with HTLV-I infection in February 2004. The original tumor in the right side of the neck disappeared after SCT, but resumed growth 2 months later. After localized irradiation of 3060 cGy and rapid reduction of immunosuppressive agents, including cyclosporine and prednisone, the tumor once again disappeared. In July 2004, the clinical features of the recipient fulfilled the criteria of acutetype ATL, and the origin of the ATL cells was confirmed to be donor-derived based on the donor-recipient chimerism status determined by PCR studies using fluorescent primers flanking an informative microsatellite region. 1 In December 2006, the donor was still healthy.
The HTLV-I provirus is randomly integrated into host genomes, and thus integration sites of the HTLV-I provirus act as a landmark of specific HTLV-I-infected cells. We first identified integration sites of the HTLV-I provirus in the donorderived ATL cells by inverse long PCR. 3 After PstI digestion followed by circularization with T4 DNA ligase, genomic DNA extracted from the donor-derived ATL cells was amplified using the following opposite primers in the pX region: pX-F, 5 0 -TGGCACGCCTATGATTTCCG-3 0 and pX-R, 5 0 -GGGGGTTGT ATGAGTGATTG-3 0 (Figure 1a , open arrows). Inverse long PCR and sequencing studies showed that one copy of the HTLV-I provirus as a complete form was integrated into chromosome 21q22.2. On the basis of the genome sequence adjacent to the HTLV-I provirus, we established the PCR method designed to amplify the junction sequence between the 3 0 -long terminal repeat (LTR) of the HTLV-I provirus and the host genome.
In our previous experiment, we were unable to detect the donor-derived ATL clone by this tumor-specific PCR method. 2 To detect a small population of specific HTLV-I-infected clones among HTLV-I-infected cells, we changed the primer designs and PCR conditions. The following primers for tumor-specific PCR were designed in the 3'-LTR of the HTLV-I provirus and the flanking genome: U5-556F, 5
0 -TGCCTGACCCTGCTTGCTC AACTCTACGTCTTTG-3 0 ; TS-637R, 5 0 -CGCTAGGCCAGAGGT GACAACTGATGGTCC-3 0 ; and TS-320R, 5 0 -CAGGCATGTGC CACCATGTCCAATTGGCAG-3 0 (Figure 1a , closed arrows). Semi-nested PCR was performed under the following conditions: 2 min at 951C for denaturation; 40 (1st PCR) or 25 (2nd PCR) cycles of 30 s at 951C, 30 s at 681C and 50 s at 721C; and 2 min at 721C for final extension. As a result, by the tumorspecific semi-nested PCR in the second round, we were able to successfully detect the donor-derived ATL clone among both
